Abstract
Objectives: Microglial overactivation, which is secondary to abnormalities of amyloid-beta peptide (Aβ) and tau proteins in the pathogenic cascade leading to onset of Alzheimers disease (AD), accelerates tau pathology, according to our recent observations using mouse models of tauopathies, and this positive feedback results in formation of a vicious cycle between upstream and downstream processes, potentially hampering effective suppression of the entire cascade by anti-amyloid treatments. This motivates our present work aimed at dual monitoring of amyloidosis and microgliosis in living animal models of AD, toward therapeutic regulation of these two processes capable of halting the self-perpetuating cycle. Methods: Transgenic mice expressing mutant amyloid precursor protein (APP23 mice) was examined by highresolution positron emission tomography (PET) after administration of amyloid probe, Pittsburg Compound B (PIB) synthesized with high specific radioactivity (SA). Microglial activation in these mice was also imaged by PET and specific tracer, [18F]fluoroethyl-DAA1106. Results: Progressive amyloidosis in APP23 mice was visualized by PET and high-SA PIB. In vitro assays revealed preferential binding of PIB to N-terminally modified Aβ, AβN3pE. As levels of this Aβ subspecies in model mice are lower than those in AD patients, our findings plausibly explain advantages of high-SA tracers in sensitive detection of mouse amyloid. Near-simultaneous monitoring of amyloid removal and microgliosis in APP23 mice following injection of anti-Aβ antibody demonstrated positive correlation between levels of initially existing amyloid and antibody-induced microglial activation, suggesting the possibility of microglial overactivation in immunotherapy for subjects with abundant amyloid. Conclusions: The present animal imaging system would substantially facilitate establishment of a safe and effective therapeutic strategy targeting multiple key processes in the AD pathogenesis.
Keywords: Amyloid, Aβ, tau, transgenic mouse, positron emission tomography, microglia, imaging biomarker
Current Alzheimer Research
Title: Visualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease
Volume: 6 Issue: 2
Author(s): Makoto Higuchi
Affiliation:
Keywords: Amyloid, Aβ, tau, transgenic mouse, positron emission tomography, microglia, imaging biomarker
Abstract: Objectives: Microglial overactivation, which is secondary to abnormalities of amyloid-beta peptide (Aβ) and tau proteins in the pathogenic cascade leading to onset of Alzheimers disease (AD), accelerates tau pathology, according to our recent observations using mouse models of tauopathies, and this positive feedback results in formation of a vicious cycle between upstream and downstream processes, potentially hampering effective suppression of the entire cascade by anti-amyloid treatments. This motivates our present work aimed at dual monitoring of amyloidosis and microgliosis in living animal models of AD, toward therapeutic regulation of these two processes capable of halting the self-perpetuating cycle. Methods: Transgenic mice expressing mutant amyloid precursor protein (APP23 mice) was examined by highresolution positron emission tomography (PET) after administration of amyloid probe, Pittsburg Compound B (PIB) synthesized with high specific radioactivity (SA). Microglial activation in these mice was also imaged by PET and specific tracer, [18F]fluoroethyl-DAA1106. Results: Progressive amyloidosis in APP23 mice was visualized by PET and high-SA PIB. In vitro assays revealed preferential binding of PIB to N-terminally modified Aβ, AβN3pE. As levels of this Aβ subspecies in model mice are lower than those in AD patients, our findings plausibly explain advantages of high-SA tracers in sensitive detection of mouse amyloid. Near-simultaneous monitoring of amyloid removal and microgliosis in APP23 mice following injection of anti-Aβ antibody demonstrated positive correlation between levels of initially existing amyloid and antibody-induced microglial activation, suggesting the possibility of microglial overactivation in immunotherapy for subjects with abundant amyloid. Conclusions: The present animal imaging system would substantially facilitate establishment of a safe and effective therapeutic strategy targeting multiple key processes in the AD pathogenesis.
Export Options
About this article
Cite this article as:
Higuchi Makoto, Visualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease, Current Alzheimer Research 2009; 6 (2) . https://dx.doi.org/10.2174/156720509787602906
DOI https://dx.doi.org/10.2174/156720509787602906 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Respiration in the Platelets of Patients with Alzheimer’s Disease
Current Alzheimer Research The Pursuit of Differentiated Ligands for the Glucocorticoid Receptor
Current Topics in Medicinal Chemistry Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism
Vascular Disease Prevention (Discontinued) Climate Changes and Human Health: A Review of the Effect of Environmental Stressors on Cardiovascular Diseases Across Epidemiology and Biological Mechanisms
Current Pharmaceutical Design Advances in Characterization of Neuroprotective Peptide, Humanin
Current Medicinal Chemistry Choline-Containing Phospholipids: Structure-Activity Relationships Versus Therapeutic Applications
Current Medicinal Chemistry Is the Use of Proton-pump Inhibitors a Risk Factor for Alzheimer’s Disease? Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Difficulties in the Management of Frontal Dementia: Therapeutics Strategies
Letters in Drug Design & Discovery Prevalence of Pathogenic Mutations in an Italian Clinical Series of Patients with Familial Dementia
Current Alzheimer Research Regional Grey Matter Loss and Brain Disconnection Across Alzheimer Disease Evolution
Current Medicinal Chemistry Brain Injury Associated with Widely Abused Amphetamines: Neuroinflammation, Neurogenesis and Blood-Brain Barrier
Current Drug Abuse Reviews In Silico Search and Toxicology Prediction of Novel Potential β-Secretase Inhibitors in Alzheimers Disease
Current Bioactive Compounds Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Prion Disease: A Deadly Disease for Protein Misfolding
Current Pharmaceutical Biotechnology Parkinson’s Disease and Alpha-Synucleinopathies: from Arising Pathways to Therapeutic Challenge
Central Nervous System Agents in Medicinal Chemistry Global View on Alzheimer’s Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer’s Disease and Diabetes Mellitus
Current Alzheimer Research The Retrogenesis Model in Alzheimer’s Disease: Evidence and Pract ical Applications
Current Psychiatry Reviews Memantine: Its Role in Vascular Dementia
Drug Design Reviews - Online (Discontinued) The Cytokine Network in HIV Infection
Current Molecular Medicine